A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary) ; Fluorouracil
  • Indications Adenocarcinoma; Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2009 Actual patient number (35) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top